Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?

Core Viewpoint - Charles River Laboratories (CRL) has experienced a slight decline of approximately 0.1% in share price over the past month, underperforming the S&P 500, raising questions about its upcoming earnings release and potential breakout [1] Group 1: Earnings Estimates - Estimates for Charles River have trended upward over the past month, with a consensus estimate shift of 7.88% [2] Group 2: VGM Scores - Charles River holds a Growth Score of B and a Momentum Score of A, with an overall aggregate VGM Score of A, indicating strong performance across multiple investment strategies [3] Group 3: Outlook - The upward trend in estimates suggests a promising outlook for Charles River, which currently holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4] Group 4: Industry Performance - Within the Zacks Medical Services industry, Avantor, Inc. (AVTR) has seen a 5.5% gain over the past month, reporting revenues of $1.58 billion for the last quarter, reflecting a year-over-year decline of 5.9% [5] - Avantor is expected to report earnings of $0.25 per share for the current quarter, with no change from the previous year, and holds a Zacks Rank of 4 (Sell) [6]